Novo Nordisk Stock Plunges 15% After Weak US Pricing Outlook for Wegovy

TIKR.com·Feb 4

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Novo Nordisk's stock has plummeted, with reports indicating a 15% drop. The decline is attributed to a weak US pricing outlook for the company's product Wegovy, despite strong earnings. However, there is some uncertainty over the reason for the drop, with one report suggesting the obesity drug fell short in a key trial, while others focus on the pricing outlook.

Full coverage

Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why

Investopedia·Feb 23

Why Did Novo Nordisk Stock Plummet Recently

Kavout | AI·Feb 16

Novo Nordisk stock tumbles 15% despite strong earnings: here’s what spooked investors

Invezz·Feb 3

Evening digest: Walmart’s $1T mark, Novo’s weak outlook, Bitcoin slips below $74K

TradingView·Feb 3

Novo stock drops 15% as obesity drug falls short in key trial

CryptoRank·Feb 23

Otis Gains 1% on Record Service Backlog: Why a 49% Valuation Gap Could Close by 2026

TIKR.com·Feb 3

5 Things to Know Before the Stock Market Opens

Investopedia·Nov 24

Raymond James Gains 1% on $1.8T Asset Milestone: Why Rising Fee Income Could Propel Shares to $250